DNLI has 36-month beta value of 1.36. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for DNLI is 124.57M, and currently, short sellers hold a 5.96% ratio of that float. The average trading volume of DNLI on November 21, 2024 was 862.89K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DNLI) stock’s latest price update
The stock of Denali Therapeutics Inc (NASDAQ: DNLI) has decreased by -0.98 when compared to last closing price of 24.42. Despite this, the company has experienced a -15.01% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-16 that Denali Therapeutics’ unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company’s strong cash position and disciplined financial strategy support its ambitious R&D and commercialization efforts without immediate need for additional funding. Denali’s pipeline targets critical neurodegenerative pathways, with promising candidates for lysosomal storage disorders, Parkinson’s disease, and neuroinflammation.
DNLI’s Market Performance
Denali Therapeutics Inc (DNLI) has seen a -15.01% fall in stock performance for the week, with a -7.29% decline in the past month and a -2.38% plunge in the past quarter. The volatility ratio for the week is 6.60%, and the volatility levels for the past 30 days are at 5.28% for DNLI. The simple moving average for the past 20 days is -11.81% for DNLI’s stock, with a 7.09% simple moving average for the past 200 days.
Analysts’ Opinion of DNLI
Citigroup gave a rating of “Buy” to DNLI, setting the target price at $32 in the report published on December 13th of the previous year.
DNLI Trading at -13.64% from the 50-Day Moving Average
After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.45% of loss for the given period.
Volatility was left at 5.28%, however, over the last 30 days, the volatility rate increased by 6.60%, as shares sank -8.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.70% lower at present.
During the last 5 trading sessions, DNLI fell by -15.18%, which changed the moving average for the period of 200-days by +42.36% in comparison to the 20-day moving average, which settled at $27.41. In addition, Denali Therapeutics Inc saw 12.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNLI starting from Schenkein David P, who sale 59,441 shares at the price of $32.51 back on Nov 11 ’24. After this action, Schenkein David P now owns 9,220 shares of Denali Therapeutics Inc, valued at $1,932,665 using the latest closing price.
Schuth Alexander O., the COFO and Secretary of Denali Therapeutics Inc, sale 15,558 shares at $29.91 during a trade that took place back on Nov 07 ’24, which means that Schuth Alexander O. is holding 178,066 shares at $465,286 based on the most recent closing price.
Stock Fundamentals for DNLI
Current profitability levels for the company are sitting at:
- 1.65 for the present operating margin
- 1.02 for the gross margin
The net margin for Denali Therapeutics Inc stands at 1.4. The total capital return value is set at -0.37. Equity return is now at value -35.09, with -31.77 for asset returns.
Based on Denali Therapeutics Inc (DNLI), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -45.13. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -23.94.
Currently, EBITDA for the company is -179.97 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of -11.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.98.
Conclusion
To put it simply, Denali Therapeutics Inc (DNLI) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
